Heat waves vs. tumors: new combo therapy for breast cancer

NCT ID NCT05889390

Ongoing Disease control Sponsor: Semmelweis University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a non-invasive heat therapy called modulated electro-hyperthermia (mEHT) to standard chemotherapy can shrink tumors more effectively in women with HER2-negative breast cancer. About 71 participants with stage II-III disease will receive chemo with or without mEHT before surgery. The main goal is to see if the combination reduces tumor size more than chemo alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: modulated electro-hyperthermia (mEHT) via Oncotherm EHY-2030 device
What this could lead to: If it works, this could improve tumor shrinkage before surgery, potentially leading to better outcomes for HER2-negative breast cancer patients.
What could go wrong: This is a mid-stage trial with only 71 participants, so results may not apply broadly. The added benefit of mEHT is unproven, and there may be side effects from the device or chemo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm Her2-receptor negative breast cancer Hyperthermia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Division of Oncology, Department of Internal Medicine and Oncology, Semmelweis University

Budapest, Budapest, 1083, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.